Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

OSLO, Norway, May 12, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for the…